If you've spent five minutes comparing GLP-1 programs, you've hit this fork in the road: semaglutide or tirzepatide? Both are effective, both are prescription-only, and both are available through the telehealth programs in our comparison table. The differences that matter are more practical than most marketing admits.
In their phase-3 obesity programs, both medications were studied with diet and exercise support:
| Semaglutide | Tirzepatide | |
|---|---|---|
| Avg. weight loss (top dose arms) | ~15% of starting weight | ~20%+ of starting weight |
| Mechanism | GLP-1 agonist | Dual GIP/GLP-1 agonist |
| Administration | Weekly injection (or daily tablets, compounded) | Weekly injection |
| Track record | Longest of the class | Shorter, extremely strong data |
| Typical program cost | ~$149–$219/mo | ~$279–$299/mo |
Read the fine print of “average.” Trial averages describe groups, not individuals. Some participants lost far more, some less. No legitimate program can promise you a number.
Providers weigh factors the internet can't: your medical history, current medications, tolerance for side effects, and whether you have conditions like thyroid issues or pancreatitis history that matter for eligibility. Cost matters too — a medication you can't sustain financially is a medication that won't work.
If you have no strong constraints, many clinicians now start with the medication that matches your budget and tolerance, then adjust after the first months based on how you respond.
Educational content only. This article is not medical advice, diagnosis, or treatment. ' 'Always consult a licensed provider about your individual situation.